EcoDrugPlus

Eph Receptor B4

Ensembl ID : ENSXETG00000011170
Gene Symbol: EPHB4
5 View Cross-references
168 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSXETG00000013500
Gene Symbol: F2RL3
7 Enzyme and pathways 5 View Cross-references
117 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSXETG00000034242
Gene Symbol: FXYD2
4 View Cross-references
137 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSXETG00000021344
Gene Symbol: FYN
53 Enzyme and pathways 5 View Cross-references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Finkel-Biskis-Reilly Murine Sarcoma Virus (Fbr-Musv) Ubiquitously Expressed

Ensembl ID : ENSXETG00000026219
Gene Symbol: FAU
5 View Cross-references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

G Protein-Coupled Receptor 119

Ensembl ID : ENSXETG00000037464
Gene Symbol: GPR119
5 View Cross-references
173 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSXETG00000024009
Gene Symbol: HCK
5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Il2-Inducible T Cell Kinase

Ensembl ID : ENSXETG00000033235
Gene Symbol: ITK
7 Enzyme and pathways 5 View Cross-references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1

Ensembl ID : ENSXETG00000023047
Gene Symbol: IMPDH1
9 Enzyme and pathways 5 View Cross-references
331 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSXETG00000009343
Gene Symbol: IMPDH2
9 Enzyme and pathways 5 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 1 (A Protein Tyrosine Kinase)

Ensembl ID : ENSXETG00000020396
Gene Symbol: JAK1
22 Enzyme and pathways 5 View Cross-references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 2 (A Protein Tyrosine Kinase)

Ensembl ID : ENSXETG00000000586
Gene Symbol: JAK2
30 Enzyme and pathways 5 View Cross-references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).